

From: rebecca.conaghan@london.biogen
Sent: Mon Aug 16 2004 11:42:40 EDT
To: dmiller@saturn.nmr.ion.ucl.ac.uk;r.gold@med.uni-goettingen.de;lkappos@uhbs.ch;ehavr@lfl.cuni.cz;ch.polman@vumc.nl;
CC: gilmore.o'neill@cambridge.biogen@biogen;
Subject: Biogen Idec Study C-1900 - Phase IIb BG12 in MS

Dear Members of the C-1900 Advisory Committee,

There has been a lot of activity since our last correspondence which we would like to take the opportunity to update you on.

Investigator Sites

We are currently in the process of setting up 43 sites across the following 10 countries: UK, Germany, Sweden, Netherlands, Switzerland, Czech Republic, Poland, Hungary, Turkey and Russia.

Ethics and regulatory submissions are well underway and I am pleased to report that we already have the following approvals:

- Central ethics committee(EC) approval in Russia
- LKP EC approval in Germany
- Conditional central EC approval in UK and Poland
- Local EC approval from all sites in Turkey
- Ministry of Health Approval in Russia
- Scientific committee approval in the Netherlands

Drug Supplies

The drug supplies are currently being packaged and are on track to be released to the sites from the end of September 2004.

MRI Reading Centre

The MRI Reading Centre has been set up with Professor Miller at the Hospital for Neurology and Neurosurgery, Queen Square in London. The MRI manual is currently being put together and will be forwarded to your site shortly.

Investigator Meeting

The investigator meeting has been scheduled for 14th and 15th September 2004 at the Trianon Palace Hotel in Versailles, France. This location was chosen in order to try to allow as many sites as possible to be able to take advantage of direct flights.

Each site is sending 2 to 3 members of their team. This will allow examining neurologists to be trained and certified on EDSS by Professor Kappos and MRI technicians will be able to gain all of the information that they will need for the study from Professor Miller's team.

We look forward to welcoming a number of you to this meeting, but we would also like to suggest that we have a short teleconference a few days prior to the meeting in order to address any of your questions or concerns about the study. If you are agreeable to this, a member of the study team will be in contact with you to arrange a convenient time.

In the meantime please do not hesitate to contact either of us should you have any questions.

With kindest regards

Gilmore O'Neill and Rebecca Conaghan

Gilmore N. O'Neill, M.B., M.R.C.P.I., M. Med. Sci.

Cambridge, MA 02142
Tel: 617-679-2000
Fax: 617-679-3518

Rebecca Conaghan
Clinical Trial Manager
Biogen Idec, UK
Tel: +44 (0) 1628 501066
Fax: +44 (0) 1628 501010